Corneal Graft Rejection - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 34 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Corneal Graft Rejection - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Corneal Graft Rejection - Pipeline Review, H2 2014', provides an overview of the Corneal Graft Rejection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Corneal Graft Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Graft Rejection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Corneal Graft Rejection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Corneal Graft Rejection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Corneal Graft Rejection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Corneal Graft Rejection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Corneal Graft Rejection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Corneal Graft Rejection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Corneal Graft Rejection Overview 6
Therapeutics Development 7
Pipeline Products for Corneal Graft Rejection - Overview 7
Pipeline Products for Corneal Graft Rejection - Comparative Analysis 8
Corneal Graft Rejection - Therapeutics under Development by Companies 9
Corneal Graft Rejection - Pipeline Products Glance 10
Early Stage Products 10
Corneal Graft Rejection - Products under Development by Companies 11
Corneal Graft Rejection - Companies Involved in Therapeutics Development 12
Oxford BioMedica plc 12
EyeGate Pharmaceuticals, Inc. 13
Icon Bioscience, Inc. 14
Corneal Graft Rejection - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 21
EncorStat - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
dexamethasone acetate - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Stromal Cell Therapy for Corneal Graft Rejection - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GB-301 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Drug for Cornea Transplant Rejection - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Corneal Graft Rejection - Recent Pipeline Updates 27
Corneal Graft Rejection - Dormant Projects 29
Corneal Graft Rejection - Product Development Milestones 30
Featured News & Press Releases 30
Aug 25, 2014: Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation 30
Apr 23, 2014: European Commission Grants Orphan Drug Designation to Soliris (Eculizumab) for the Prevention of Graft Rejection Following Solid Organ Transplantation 31
Jan 30, 2012: VGX-100 Identified As Potential New Therapy For Improving Corneal Graft Survival 31
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Number of Products under Development for Corneal Graft Rejection, H2 2014 7
Number of Products under Development for Corneal Graft Rejection - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Development, H2 2014 10
Products under Development by Companies, H2 2014 11
Corneal Graft Rejection - Pipeline by Oxford BioMedica plc, H2 2014 12
Corneal Graft Rejection - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2014 13
Corneal Graft Rejection - Pipeline by Icon Bioscience, Inc., H2 2014 14
Assessment by Monotherapy Products, H2 2014 15
Number of Products by Stage and Target, H2 2014 16
Number of Products by Stage and Mechanism of Action, H2 2014 17
Number of Products by Stage and Route of Administration, H2 2014 19
Number of Products by Stage and Molecule Type, H2 2014 20
Corneal Graft Rejection Therapeutics - Recent Pipeline Updates, H2 2014 27
Corneal Graft Rejection - Dormant Projects, H2 2014 29